It is a snapshot as of now. They don note future catalysts which will affect their valuation:
Future Material Catalysts:
■ ACAD announcements, particularly: DAYBUE sales results + ROW launch
■ Remaining study outcomes + NEU's progression &/or licensing of NNZ-2591
■ Clinical development of NNZ-2591 in Rett or Fragile X syndrome by ACAD
■ News flow around competing therapeutics for Rett or other indications, noting that
the nearest competing drug to DAYBUE, Anavex's blarcamesine 2-73 recently
failed to meet its study endpoints in paediatric Rett patients.
It is a snapshot as of now. They don note future catalysts which...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.03 |
Change
-0.170(0.89%) |
Mkt cap ! $2.419B | |||
| Open | High | Low | Value | Volume |
| $18.76 | $19.13 | $18.71 | $3.114M | 164.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 325 | $19.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.05 | 55 | 5 |
View Market Depth
| Last trade - 12.36pm 01/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.11 |
Change
-0.170 ( 0.78 %) |
||||
| Open | High | Low | Volume | ||
| $18.80 | $19.15 | $18.73 | 50500 | ||
| Last updated 12.55pm 01/05/2024 ? | |||||
| NEU (ASX) Chart |